{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:05:06Z","timestamp":1791050706188,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma (GBM) is often complicated by venous thromboembolism (VTE), primarily driven by tissue factor (TF,\n                    <jats:italic>F3<\/jats:italic>\n                    ) and podoplanin (PDPN). These factors promote local hypercoagulation and microthrombosis, thereby contributing to tumor progression by enhancing migration, invasion, and inflammation. Both TF and PDPN can be released via extracellular vesicles (EVs), which carry procoagulant and immunomodulatory cargo. We developed a translational workflow combining biobanked tumor samples, clinical data, ex vivo GBM cultures, and coagulation assays to investigate mechanisms of hypercoagulation. Intraoperative blood coagulation was profiled using ClotPro\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . Gene expression of coagulation-related markers was analyzed in tumor tissues and cell lines, complemented by RNAseq-based profiling of coagulation\u2013inflammation links. Functional coagulation assays included clotting time, platelet aggregation, and EV-based analysis of prothrombotic and immunomodulatory activity. Peripheral coagulation in GBM patients was largely unaltered. However, tumor tissues consistently showed high\n                    <jats:italic>F3<\/jats:italic>\n                    and\n                    <jats:italic>PDPN<\/jats:italic>\n                    expression and markedly low tissue factor pathway inhibitor (\n                    <jats:italic>TFPI<\/jats:italic>\n                    ) levels (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), indicating a shift toward a procoagulant phenotype. Patient-derived GBM cell lines showed variable\n                    <jats:italic>TF<\/jats:italic>\n                    and\n                    <jats:italic>PDPN<\/jats:italic>\n                    expression, which correlated with clotting potential. Distinct procoagulant mechanisms were observed, with some cells engaging both TF-mediated thrombin generation and PDPN-driven platelet activation. EVs isolated from GBM patient plasma and culture media showed similar procoagulant characteristics, with activity proportional to TF expression, and immune-modulating effects. Notably, GBM-derived EVs modulated microglial behavior, induced senescence, and triggered immune polarization in a cell line-dependent manner, likely contributing to tumor microenvironment remodeling. GBM-associated hypercoagulability is shaped by heterogeneous tumor-intrinsic pathways and EV-mediated mechanisms. The dual role of EVs in promoting coagulation and modulating immune responses provides a mechanistic framework for further studies investigating EVs as potential biomarkers and therapeutic targets relevant to future thromboprophylactic strategies in GBM patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-42867-4","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:26:01Z","timestamp":1773915961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the dual role of extracellular vesicles in coagulation and immune modulation in glioblastoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Annabell","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Waitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Kaps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Oehmcke-Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Bergmann-Ewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sophie","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Freiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Troschke-Meurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Maletzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"Suppl","key":"42867_CR1","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0049-3848(16)30096-2","volume":"140","author":"E D\u2019Asti","year":"2016","unstructured":"D\u2019Asti, E. & Rak, J. Biological basis of personalized anticoagulation in cancer: Oncogene and oncomir networks as putative regulators of coagulopathy. Thromb. Res. 140(Suppl), S37\u2013S43. https:\/\/doi.org\/10.1016\/S0049-3848(16)30096-2 (2016).","journal-title":"Thromb. Res."},{"key":"42867_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6792850","author":"WJ Zeng","year":"2022","unstructured":"Zeng, W. J. et al. A novel thrombosis-related signature for predicting survival and drug compounds in Glioblastoma. J. Oncol. https:\/\/doi.org\/10.1155\/2022\/6792850 (2022).","journal-title":"J. Oncol."},{"issue":"7","key":"42867_CR3","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/jth.15739","volume":"20","author":"FHJ Kaptein","year":"2022","unstructured":"Kaptein, F. H. J. et al. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. J. Thromb. Haemost. 20(7), 1665\u20131673. https:\/\/doi.org\/10.1111\/jth.15739 (2022).","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"42867_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1055\/s-0039-1687891","volume":"45","author":"N Tawil","year":"2019","unstructured":"Tawil, N., Bassawon, R. & Rak, J. Oncogenes and clotting factors: The emerging role of tumor cell genome and epigenome in cancer-associated thrombosis. Semin. Thromb. Hemost. 45(4), 373\u2013384. https:\/\/doi.org\/10.1055\/s-0039-1687891 (2019).","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"42867_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3892\/OL.2016.4593\/HTML","volume":"12","author":"RQ Monteiro","year":"2016","unstructured":"Monteiro, R. Q. et al. Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. Oncol. Lett. 12(1), 315\u2013322. https:\/\/doi.org\/10.3892\/OL.2016.4593\/HTML (2016).","journal-title":"Oncol. Lett."},{"issue":"4","key":"42867_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0009-9120(02)00312-0","volume":"35","author":"M Guan","year":"2002","unstructured":"Guan, M., Jin, J., Su, B., Liu, W. W. & Lu, Y. Tissue factor expression and angiogenesis in human glioma. Clin. Biochem. 35(4), 321\u2013325. https:\/\/doi.org\/10.1016\/S0009-9120(02)00312-0 (2002).","journal-title":"Clin. Biochem."},{"issue":"1","key":"42867_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/BLOOD.V64.1.177.177","volume":"64","author":"E Bastida","year":"1984","unstructured":"Bastida, E., Ordinas, A., Escolar, G. & Jamieson, G. A. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 64(1), 177\u2013184. https:\/\/doi.org\/10.1182\/BLOOD.V64.1.177.177 (1984).","journal-title":"Blood"},{"issue":"2","key":"42867_CR8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1160\/TH12-12-0957","volume":"110","author":"MT Sartori","year":"2013","unstructured":"Sartori, M. T. et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: A potential prothrombotic role. Thromb. Haemost. 110(2), 378\u2013385. https:\/\/doi.org\/10.1160\/TH12-12-0957 (2013).","journal-title":"Thromb. Haemost."},{"issue":"6","key":"42867_CR9","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1182\/BLOODADVANCES.2020002998","volume":"5","author":"N Tawil","year":"2021","unstructured":"Tawil, N. et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 5(6), 1682\u20131694. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020002998 (2021).","journal-title":"Blood Adv."},{"issue":"11","key":"42867_CR10","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1182\/BLOOD.2022017858","volume":"141","author":"KB Burdett","year":"2023","unstructured":"Burdett, K. B. et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 141(11), 1322\u20131336. https:\/\/doi.org\/10.1182\/BLOOD.2022017858 (2023).","journal-title":"Blood"},{"issue":"5","key":"42867_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/cas.13580","volume":"109","author":"H Krishnan","year":"2018","unstructured":"Krishnan, H. et al. Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Sci. 109(5), 1292\u20131299. https:\/\/doi.org\/10.1111\/cas.13580 (2018).","journal-title":"Cancer Sci."},{"issue":"13","key":"42867_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714.Podoplanin","volume":"129","author":"R J","year":"2017","unstructured":"J, R. et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 129(13), 1831\u20131839. https:\/\/doi.org\/10.1182\/blood-2016-06-720714.Podoplanin (2017).","journal-title":"Blood"},{"issue":"2","key":"42867_CR13","doi-asserted-by":"publisher","first-page":"pp1","DOI":"10.1002\/cnr2.1699","volume":"6","author":"JS de Bono","year":"2023","unstructured":"de Bono, J. S. et al. Systematic study of tissue factor expression in solid tumors. Cancer Rep. 6 (2), pp1\u201311. https:\/\/doi.org\/10.1002\/cnr2.1699 (2023).","journal-title":"Cancer Rep."},{"issue":"3","key":"42867_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-008-9579-4","volume":"88","author":"CA Scrideli","year":"2008","unstructured":"Scrideli, C. A. et al. Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: Identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J. Neurooncol. 88(3), 281\u2013291. https:\/\/doi.org\/10.1007\/s11060-008-9579-4 (2008).","journal-title":"J. Neurooncol."},{"key":"42867_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS16234051","author":"B Sharma","year":"2024","unstructured":"Sharma, B. et al. Role of Podoplanin (PDPN) in advancing the progression and metastasis of Glioblastoma Multiforme (GBM). Cancers https:\/\/doi.org\/10.3390\/CANCERS16234051 (2024).","journal-title":"Cancers"},{"issue":"6","key":"42867_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325964","volume":"20","author":"S Long","year":"2025","unstructured":"Long, S. et al. Predicting podoplanin expression and prognostic significance in high-grade glioma based on TCGA TCIA radiomics. PLoS One 20(6), e0325964. https:\/\/doi.org\/10.1371\/journal.pone.0325964 (2025).","journal-title":"PLoS One"},{"issue":"4","key":"42867_CR17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/0008-5472.CAN-04-3376","volume":"65","author":"Y Rong","year":"2005","unstructured":"Rong, Y. et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 65(4), 1406\u20131413. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3376 (2005).","journal-title":"Cancer Res."},{"key":"42867_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2301633","author":"P Li","year":"2024","unstructured":"Li, P., Ma, X. & Huang, G. Understanding thrombosis: The critical role of oxidative stress. Hematology https:\/\/doi.org\/10.1080\/16078454.2023.2301633 (2024).","journal-title":"Hematology"},{"issue":"1","key":"42867_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm0196-35","volume":"2","author":"P Golino","year":"1996","unstructured":"Golino, P. et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat. Med. 2(1), 35\u201340. https:\/\/doi.org\/10.1038\/nm0196-35 (1996).","journal-title":"Nat. Med."},{"key":"42867_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02233-w","author":"L Kuang","year":"2025","unstructured":"Kuang, L., Wu, L. & Li, Y. Extracellular vesicles in tumor immunity: Mechanisms and novel insights. Mol. Cancer https:\/\/doi.org\/10.1186\/s12943-025-02233-w (2025).","journal-title":"Mol. Cancer"},{"issue":"8","key":"42867_CR21","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ccell.2023.06.007","volume":"41","author":"HM Jeon","year":"2023","unstructured":"Jeon, H. M. et al. Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer Cell 41(8), 1480-1497.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.06.007 (2023).","journal-title":"Cancer Cell"},{"issue":"1","key":"42867_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-024-01705-8","volume":"22","author":"HY Kim","year":"2024","unstructured":"Kim, H. Y. & Kim, H. S. Podoplanin depletion in tonsil-derived mesenchymal stem cells induces cellular senescence via regulation of the p16Ink4a\/Rb pathway. Cell Commun. Signal. 22(1), 1\u201315. https:\/\/doi.org\/10.1186\/s12964-024-01705-8 (2024).","journal-title":"Cell Commun. Signal."},{"issue":"9","key":"42867_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/iai.00476-23","volume":"92","author":"AM Marrufo","year":"2024","unstructured":"Marrufo, A. M. & Flores-Mireles, A. L. Macrophage fate: To kill or not to kill?. Infect. Immun. 92(9), 1\u201322. https:\/\/doi.org\/10.1128\/iai.00476-23 (2024).","journal-title":"Infect. Immun."},{"issue":"6","key":"42867_CR24","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1002\/jcb.28260","volume":"120","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. PAR2 promotes M1 macrophage polarization and inflammation via FOXO1 pathway. J. Cell. Biochem. 120(6), 9799\u20139809. https:\/\/doi.org\/10.1002\/jcb.28260 (2019).","journal-title":"J. Cell. Biochem."},{"key":"42867_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14643","author":"M Wu","year":"2024","unstructured":"Wu, M. et al. Exosome-transmitted podoplanin promotes tumor\u2010associated macrophage\u2010mediated immune tolerance in glioblastoma. CNS Neurosci. Ther. https:\/\/doi.org\/10.1111\/cns.14643 (2024).","journal-title":"CNS Neurosci. Ther."},{"issue":"April","key":"42867_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1346587","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Tumor-derived extracellular vesicles regulate macrophage polarization: Role and therapeutic perspectives. Front. Immunol. 15(April), 1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2024.1346587 (2024).","journal-title":"Front. Immunol."},{"issue":"May","key":"42867_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1183465","volume":"14","author":"DS Rubenich","year":"2023","unstructured":"Rubenich, D. S. et al. Tumor-neutrophil crosstalk promotes in vitro and in vivo glioblastoma progression. Front. Immunol. 14(May), 1\u201317. https:\/\/doi.org\/10.3389\/fimmu.2023.1183465 (2023).","journal-title":"Front. Immunol."},{"issue":"1","key":"42867_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06893-7","volume":"7","author":"AC Leal","year":"2017","unstructured":"Leal, A. C. et al. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: Implications for the establishment of cancer-associated thrombosis. Sci. Rep. 7(1), 1\u201312. https:\/\/doi.org\/10.1038\/s41598-017-06893-7 (2017).","journal-title":"Sci. Rep."},{"key":"42867_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/S41698-024-00653-3","author":"T Freitag","year":"2024","unstructured":"Freitag, T. et al. Combined inhibition of EZH2 and CDK4\/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma. npj Precis. Oncol. https:\/\/doi.org\/10.1038\/S41698-024-00653-3 (2024).","journal-title":"npj Precis. Oncol."},{"key":"42867_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030904","author":"S Troschke-Meurer","year":"2023","unstructured":"Troschke-Meurer, S. et al. Chemotherapeutics used for high-risk neuroblastoma therapy improve the efficacy of anti-GD2 antibody Dinutuximab Beta in preclinical spheroid models. Cancers https:\/\/doi.org\/10.3390\/cancers15030904 (2023).","journal-title":"Cancers"},{"issue":"1","key":"42867_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2022.2148850","volume":"11","author":"H Forkel","year":"2022","unstructured":"Forkel, H. et al. BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood \u03b1\u03b2 CD8\u2009+\u2009T cells. Oncoimmunology 11(1), 1\u201318. https:\/\/doi.org\/10.1080\/2162402X.2022.2148850 (2022).","journal-title":"Oncoimmunology"},{"key":"42867_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2094583","author":"I Salewski","year":"2022","unstructured":"Salewski, I. et al. CDK4 \/ 6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors. Oncoimmunology https:\/\/doi.org\/10.1080\/2162402X.2022.2094583 (2022).","journal-title":"Oncoimmunology"},{"issue":"24","key":"42867_CR33","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1182\/bloodadvances.2020002372","volume":"4","author":"K Jahn","year":"2020","unstructured":"Jahn, K. et al. Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro. Blood Adv. 4(24), 6315\u20136326. https:\/\/doi.org\/10.1182\/bloodadvances.2020002372 (2020).","journal-title":"Blood Adv."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42867-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:29:27Z","timestamp":1781641767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42867-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42867"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42867-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Blood samples from GBM patients and cell lines established from tumor tissue were obtained with written informed consent from all participants. All procedures were approved by the Ethics Committee of the Rostock University Medical Center, University of Rostock (Ethics Registration ID: A2018-0167), and conducted in accordance with internationally accepted guidelines for the use of human biological material.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9534"}}